CORONAVIRUS | Novavax Inc said on Tuesday its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10 percent.

The company said it would start a large pivotal Phase III trial as soon as late September, and on a conference call added that it could produce one billion to two billion doses of the vaccine in 2021...